Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
1.590
-0.140 (-8.09%)
At close: Nov 20, 2024, 4:00 PM
1.540
-0.050 (-3.14%)
Pre-market: Nov 21, 2024, 5:50 AM EST
Atai Life Sciences Employees
Atai Life Sciences had 83 employees as of December 31, 2023. The number of employees decreased by 50 or -37.59% compared to the previous year.
Employees
83
Change (1Y)
-50
Growth (1Y)
-37.59%
Revenue / Employee
$3,988
Profits / Employee
-$1,549,434
Market Cap
266.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83 | -50 | -37.59% |
Dec 31, 2022 | 133 | 46 | 52.87% |
Dec 31, 2021 | 87 | 52 | 148.57% |
Dec 31, 2020 | 35 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
AngioDynamics | 748 |
OraSure Technologies | 638 |
Sage Therapeutics | 487 |
Vanda Pharmaceuticals | 203 |
Nautilus Biotechnology | 167 |
Voyager Therapeutics | 162 |
iTeos Therapeutics | 157 |
ATAI News
- 7 weeks ago - IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG - GlobeNewsWire
- 2 months ago - atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Psychedelic Stock Deep Dive: Atai Life Sciences - Seeking Alpha
- 3 months ago - atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Psychedelic drug contender stocks drop after FDA rejects MDMA treatment - Market Watch
- 3 months ago - atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference - GlobeNewsWire
- 5 months ago - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - GlobeNewsWire
- 5 months ago - atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - GlobeNewsWire